• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Science & Research

  • Print
  • Share
  • E-mail

Public Engagement

The FDA is working with consumers, industry groups, non-profit organizations, and academia on issues relating to nanotechnology and to implement recommendations outlined in the 2007 Nanotechnology Task Force Report.  The Agency recognizes the importance of public engagement in developing a regulatory strategy for products containing nanoscale material and seeks to include the public at all stages of the process.


Two public meetings were held in October 2006 and September 2008.  The purpose of these meetings was to help FDA further its understanding of developments in the use of nanoscale materials in FDA-regulated products.  The October 2008 meeting additionally sought out information to assist the Agency in implementing recommendations included in the Nanotechnology Task Force Report relating to the development of agency guidances. The Report's recommendations covered foods (including dietary supplements), food and color additives (including food contact substances), animal drugs and feeds, cosmetics, human drugs, biologics, and medical devices.  In addition to requesting comments on specific questions included in the meeting notice, FDA announced a request for available data and information on the effects of nanoscale materials on quality, safety, and, where relevant, effectiveness of products subject to FDA oversight.